FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234700006> ?p ?o ?g. }

• W4234700006 endingPage "970" @default.
• W4234700006 startingPage "963" @default.
• W4234700006 abstract "We evaluated the effects of tranexamic acid (TA) administered before and after cardiopulmonary bypass (CPB) in a prospective, randomized, placebo-controlled, double-blind study of adult patients undergoing primary coronary artery by pass grafting surgery. Patients received placebo (n = 30) or TA 15 mg/kg before CPB, followed by a TA infusion of 1 mg [center dot] kg-1 [center dot] h-1 for 5 h (n = 30) or TA 15 mg/kg after CPB, followed by a TA infusion of 1 mg [center dot] kg-1 [center dot] h-1 for 5 h (n = 30). Demographic, medical, surgical, laboratory, mediastinal chest tube drainage (MCTD), hemoglobin loss, transfusion, and outcome data were collected. Allogenic blood product administration was tightly controlled. The demographic, medical, and surgical characteristics were similar in all three groups. The median postoperative MCTD and hemoglobin loss in the pre-CPB TA group (710 mL, 8.6 g) was significantly less (P < 0.001) compared with the control (1202 mL, 44.2 g) and post-CPB TA groups (1020 mL, 23.4 g). The percentage of patients who received no allogenic blood products was 27% for the pre-CPB TA group and 33% for the post-CPB TA group (not significant). These percentages were significantly lower than those in the placebo group (66%, P < 0.001). The median number of allogenic blood products administered to the pre-CPB TA group (0 units) was significantly less compared with the control group (4.5 units). The thromboelastogram and fibrinogen split product levels in the pre-CPB TA group indicated better platelet function and less activation of the fibrinolytic system compared with the other two groups (P < 0.05). There were no intergroup differences in reoperation, myocardial infarction, stroke, infections, or death. These data support the use of pre-CPB TA to decrease patient exposure to postcardiopulmonary bypass allogenic blood products. Implications: In this randomized, placebo-controlled trial, we investigated the efficacy of tranexamic acid to decrease bleeding and blood transfusions after open-heart operations. Tranexamic acid administered before and during the operation was effective in decreasing both bleeding and transfusions. When tranexamic acid was administered immediately after the operation, it had a minor beneficial effect. (Anesth Analg 1997;85:963-70)" @default.
• W4234700006 created "2022-05-12" @default.
• W4234700006 creator A5046229365 @default.
• W4234700006 creator A5063169610 @default.
• W4234700006 creator A5089474485 @default.
• W4234700006 date "1997-11-01" @default.
• W4234700006 modified "2023-10-16" @default.
• W4234700006 title "Tranexamic Acid Is Effective in Decreasing Postoperative Bleeding and Transfusions in Primary Coronary Artery Bypass Operations" @default.
• W4234700006 cites W144291087 @default.
• W4234700006 cites W1516463094 @default.
• W4234700006 cites W1951611637 @default.
• W4234700006 cites W1970914881 @default.
• W4234700006 cites W1978189470 @default.
• W4234700006 cites W1978767469 @default.
• W4234700006 cites W1983199628 @default.
• W4234700006 cites W1983338441 @default.
• W4234700006 cites W198708118 @default.
• W4234700006 cites W1995983649 @default.
• W4234700006 cites W2024605653 @default.
• W4234700006 cites W2032728373 @default.
• W4234700006 cites W2033180498 @default.
• W4234700006 cites W2050483671 @default.
• W4234700006 cites W2068845415 @default.
• W4234700006 cites W2068905052 @default.
• W4234700006 cites W2071688536 @default.
• W4234700006 cites W2077935285 @default.
• W4234700006 cites W2095683991 @default.
• W4234700006 cites W2097715477 @default.
• W4234700006 cites W229396605 @default.
• W4234700006 cites W2304916447 @default.
• W4234700006 cites W2408971219 @default.
• W4234700006 cites W2410498513 @default.
• W4234700006 cites W2414491935 @default.
• W4234700006 doi "https://doi.org/10.1213/00000539-199711000-00003" @default.
• W4234700006 hasPublicationYear "1997" @default.
• W4234700006 type Work @default.
• W4234700006 citedByCount "86" @default.
• W4234700006 countsByYear W42347000062012 @default.
• W4234700006 countsByYear W42347000062013 @default.
• W4234700006 countsByYear W42347000062014 @default.
• W4234700006 countsByYear W42347000062015 @default.
• W4234700006 countsByYear W42347000062016 @default.
• W4234700006 countsByYear W42347000062017 @default.
• W4234700006 countsByYear W42347000062018 @default.
• W4234700006 countsByYear W42347000062019 @default.
• W4234700006 countsByYear W42347000062020 @default.
• W4234700006 countsByYear W42347000062021 @default.
• W4234700006 countsByYear W42347000062022 @default.
• W4234700006 crossrefType "journal-article" @default.
• W4234700006 hasAuthorship W4234700006A5046229365 @default.
• W4234700006 hasAuthorship W4234700006A5063169610 @default.
• W4234700006 hasAuthorship W4234700006A5089474485 @default.
• W4234700006 hasBestOaLocation W42347000061 @default.
• W4234700006 hasConcept C126322002 @default.
• W4234700006 hasConcept C141071460 @default.
• W4234700006 hasConcept C142724271 @default.
• W4234700006 hasConcept C204787440 @default.
• W4234700006 hasConcept C27081682 @default.
• W4234700006 hasConcept C2775901492 @default.
• W4234700006 hasConcept C2776820930 @default.
• W4234700006 hasConcept C2777396833 @default.
• W4234700006 hasConcept C2778789114 @default.
• W4234700006 hasConcept C2778881276 @default.
• W4234700006 hasConcept C2778917026 @default.
• W4234700006 hasConcept C2779637338 @default.
• W4234700006 hasConcept C2780014101 @default.
• W4234700006 hasConcept C2991743468 @default.
• W4234700006 hasConcept C42219234 @default.
• W4234700006 hasConcept C71924100 @default.
• W4234700006 hasConceptScore W4234700006C126322002 @default.
• W4234700006 hasConceptScore W4234700006C141071460 @default.
• W4234700006 hasConceptScore W4234700006C142724271 @default.
• W4234700006 hasConceptScore W4234700006C204787440 @default.
• W4234700006 hasConceptScore W4234700006C27081682 @default.
• W4234700006 hasConceptScore W4234700006C2775901492 @default.
• W4234700006 hasConceptScore W4234700006C2776820930 @default.
• W4234700006 hasConceptScore W4234700006C2777396833 @default.
• W4234700006 hasConceptScore W4234700006C2778789114 @default.
• W4234700006 hasConceptScore W4234700006C2778881276 @default.
• W4234700006 hasConceptScore W4234700006C2778917026 @default.
• W4234700006 hasConceptScore W4234700006C2779637338 @default.
• W4234700006 hasConceptScore W4234700006C2780014101 @default.
• W4234700006 hasConceptScore W4234700006C2991743468 @default.
• W4234700006 hasConceptScore W4234700006C42219234 @default.
• W4234700006 hasConceptScore W4234700006C71924100 @default.
• W4234700006 hasIssue "5" @default.
• W4234700006 hasLocation W42347000061 @default.
• W4234700006 hasLocation W42347000062 @default.
• W4234700006 hasOpenAccess W4234700006 @default.
• W4234700006 hasPrimaryLocation W42347000061 @default.
• W4234700006 hasRelatedWork W1979249554 @default.
• W4234700006 hasRelatedWork W2006868423 @default.
• W4234700006 hasRelatedWork W2086041793 @default.
• W4234700006 hasRelatedWork W2158002217 @default.
• W4234700006 hasRelatedWork W2199561368 @default.
• W4234700006 hasRelatedWork W2518597740 @default.
• W4234700006 hasRelatedWork W3000526881 @default.
• W4234700006 hasRelatedWork W3017135163 @default.

• next